<?xml version="1.0" encoding="UTF-8"?>
<p>From February 2020, the LF efficacy against SARS-CoV-2 has been reviewed since this protein showed promising antiviral and anti-inflammatory properties reducing the typical “cytokine storm” in COVID-19 patients [
 <xref rid="B52-molecules-26-00632" ref-type="bibr">52</xref>,
 <xref rid="B67-molecules-26-00632" ref-type="bibr">67</xref>,
 <xref rid="B68-molecules-26-00632" ref-type="bibr">68</xref>]. Based on the encouraging preliminary results, several clinical trials have been registered but, the only clinical trial concluded was the one of Campione et al. [
 <xref rid="B67-molecules-26-00632" ref-type="bibr">67</xref>]. According to the authors, LF might be used in asymptomatic or mildly symptomatic patients to prevent the worsening of SARS-CoV-2. However, despite the courageous preliminary results, more adequate and well-drawn clinical trials should be carried out to evaluate the useful, beneficial properties of LF for COVID-19 disease.
</p>
